TNF Inhibitor denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for TNF Inhibitors

TNF inhibitors are high-cost biologic medications, and Blue Cross Blue Shield — like nearly all commercial insurers — requires prior authorization (PA) before dispensing them. A PA-required denial means your prescription was filled or submitted without an approved authorization on file, or that an authorization request was submitted but not yet approved. This is one of the most common denial types for specialty biologics and one of the most straightforward to address.

## Why This Denial Is Appealable (and Often Avoidable)

If a PA was submitted and denied on clinical grounds, you have full appeal rights. If no PA was submitted, the path is to submit one now rather than to file a formal appeal — though you can also request a retroactive authorization in some circumstances. Either way, the clinical evidence standards are the same: you need to show your diagnosis, disease severity, and prior-treatment history satisfy the BCBS coverage criteria.

## Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or state insurance regulations (individual/fully-insured plans), you may appeal any adverse benefit determination, including a PA denial, with a full-and-fair review by someone not involved in the original decision.
• External review (ACA §2719): After exhausting internal appeals, you may request independent external review, typically within four months of the final internal denial.
• Expedited review: If you are currently on this medication and face interruption, or if your condition is clinically urgent, request expedited review. Decisions are generally required within 72 hours.

## Documentation to Gather

1. Completed PA form: Obtain the current BCBS prior-authorization form for the specific TNF inhibitor and your diagnosis. Confirm the form is current — outdated forms are a common cause of delay. 2. Diagnosis documentation: Recent chart notes establishing the diagnosis, its severity, and its duration. 3. Step-therapy compliance evidence: Records showing you have tried the conventional or non-biologic therapies BCBS requires before approving a biologic, including start/stop dates and reasons for discontinuation. 4. Prescriber medical-necessity letter: A letter from your treating physician addressing each PA criterion directly, citing the relevant specialty-society guideline (e.g., ACR, AAD, AGA) and explaining why the requested TNF inhibitor is appropriate. 5. BCBS PA criteria: Download or request the current published PA criteria so your submission addresses every requirement.

## Criteria-Mapping Structure

| PA Requirement | Your Supporting Documentation | |---|---| | Qualifying diagnosis | [Diagnosis, date, confirming notes or test] | | Required prior therapies completed | [Each drug, dates, response or reason stopped] | | Disease severity meets policy threshold | [Physician assessment in chart] | | Prescriber attestation | [Letter date and prescriber credentials] |

The most important step is obtaining the exact PA criteria document BCBS uses for your drug and diagnosis, then ensuring every line is addressed in your submission. Incomplete submissions — not clinical ineligibility — are the leading cause of PA delays.